Cd22 Delta E12 As A Molecular Target For Corrective Repair Using Rna Trans-Splicing: Anti-Leukemic Activity Of A Rationally Designed Rna Trans-Splicing Molecule

Our recent studies have demonstrated that the CD22 exon 12 deletion (CD22 Delta E12) is a characteristic genetic defect of therapy-refractory clones in pediatric B-precursor acute lymphoblastic leukemia (BPL) and implicated the CD22 Delta E12 genetic defect in the aggressive biology of relapsed or therapy-refractory pediatric BPL. The purpose of the present study was to further evaluate the biologic significance of the CD22 Delta E12 molecular lesion and determine if it could serve as a molecular target for corrective repair using RNA trans-splicing therapy. We show that both pediatric and adult B-lineage lymphoid malignancies are characterized by a very high incidence of the CD22 Delta E12 genetic defect. We provide experimental evidence that the correction of the CD22 Delta E12 genetic defect in human CD22 Delta E12(+) BPL cells using a rationally designed CD22 RNA trans-splicing molecule (RTM) caused a pronounced reduction of their clonogenicity. The RTM-mediated correction replaced the downstream mutation-rich segment of Intron 12 and remaining segments of the mutant CD22 pre-mRNA with wildtype CD22 exons 10-14, thereby preventing the generation of the cis-spliced aberrant CD22 Delta E12 product. The anti-leukemic activity of this RTM against BPL xenograft clones derived from CD22 Delta E12(+) leukemia patients provides the preclinical proof-of-concept that correcting the CD22 Delta E12 defect with rationally designed CD22 RTMs may provide the foundation for therapeutic innovations that are needed for successful treatment of high-risk and relapsed BPL patients.